Shanghai Henlius Biotech, Inc. (2696.HK) on Thursday announced that HANSIZHUANG, used in combination with chemotherapy, has successfully met the primary endpoint of event-free survival (EFS) in an interim analysis of its phase 3 study.
The study, dubbed ASTRUM-006, is designed to evaluate the efficacy and safety of HANSIZHUANG , used in combination with chemotherapy, as a neoadjuvant/adjuvant monotherapy treatment for patients with early-stage gastric cancer, compared to a placebo plus chemotherapy regimen.
Based on the positive results, the Independent Data Monitoring Committee has recommended that the company submit an early New Drug Application (NDA) for HANSIZHUANG.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.